Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.
Gerontology. 2023;69(10):1167-1174. doi: 10.1159/000530795. Epub 2023 Apr 25.
Measuring the abundance of biological molecules and their chemical modifications in blood and tissues has been the cornerstone of research and medical diagnoses for decades. Although the number and variety of molecules that can be measured have expanded exponentially, the blood biomarkers routinely assessed in medical practice remain limited to a few dozen, which have not substantially changed over the last 30-40 years. The discovery of novel biomarkers would allow, for example, risk stratification or monitoring of disease progression or the effectiveness of treatments and interventions, improving clinical practice in myriad ways. In this review, we combine the biomarker discovery concept with geroscience. Geroscience bridges aging research and translation to clinical applications by combining the framework of medical gerontology with high-technology medical research. With the development of geroscience and the rise of blood biomarkers, there has been a paradigm shift from disease prevention and cure to promoting health and healthy aging. New -omic technologies have played a role in the development of blood biomarkers, including epigenetic, proteomic, metabolomic, and lipidomic markers, which have emerged as correlates or predictors of health status, from disease to exceptional health.
几十年来,测量血液和组织中生物分子的丰度及其化学修饰一直是研究和医学诊断的基石。尽管可测量的分子数量和种类呈指数级增长,但在医学实践中常规评估的血液生物标志物仍然局限于几十种,而且在过去 30-40 年中并没有实质性变化。新型生物标志物的发现将允许例如对疾病进展或治疗和干预措施的效果进行风险分层或监测,从而以多种方式改善临床实践。在这篇综述中,我们将生物标志物发现的概念与衰老科学相结合。衰老科学通过将医学老年学框架与高科技医学研究相结合,将衰老研究与转化到临床应用联系起来。随着衰老科学的发展和血液生物标志物的兴起,已经从疾病的预防和治疗转变为促进健康和健康衰老的范式转变。新的组学技术在血液生物标志物的发展中发挥了作用,包括表观遗传、蛋白质组学、代谢组学和脂质组学标记物,这些标记物已成为从疾病到卓越健康的健康状况的相关或预测因素。